Rifampin alone or with trimethoprim for contacts of children with Haemophilus influenzae type b infections.
We carried out a nonrandomized, unblinded study to compare the efficacy of rifampin alone with that of rifampin in combination with trimethoprim in the eradication of the Haemophilus influenzae type b (HIB) carrier state among contacts of patients with invasive HIB infection. The study population comprised 17 index patients admitted to hospital with severe HIB infections and 233 contacts, 43 of whom had nasopharyngeal colonization with HIB of the same biotype as that of the index patient. Rifampin in a daily dose of 20 mg/kg (maximum 600 mg) for 4 days eradicated the carrier state in 86% of cases, as did the combination of rifampin at the same dosage and trimethoprim in a daily dose of 5 mg/kg (maximum 160 mg) for 4 days.
D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004826:Epiglottitis / Q000188:drug therapy; D005500:Follow-Up Studies; D006192:Haemophilus Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008583:Meningitis, Haemophilus / Q000188:drug therapy; D008826:Microbial Sensitivity Tests; D012293:Rifampin / Q000008:administration & dosage*; D014295:Trimethoprim / Q000008:administration & dosage*
D014295:Trimethoprim; D012293:Rifampin